Theranexus, Diverchim and INSERM obtain funding of 4.7 million euros for the development of a new antisense oligonucleotide

As part of the France 2030 call for projects "Innovations in Biotherapies and Bioproduction", the PickASO consortium, made up of Theranexus, Diverchim and the ARNA laboratory of INSERM, receives funding of 4.7 million euros. This financial support will make it possible to develop a therapy based on the activation of autophagy to treat rare neurological diseases.

Theranexus, leader of the project, collaborates with Diverchim for the synthesis of active ingredients and with the INSERM unit to provide its expertise in the field of antisense oligonucleotides. The project will benefit from a grant and repayable advances over three years managed by Bpifrance.

The therapy in development targets TFEB, a crucial protein in the process of cellular autophagy. This treatment mainly targets lysosomal diseases and other neurodegenerative pathologies where autophagy is deficient. Diverchim will provide its expertise in Good Manufacturing Practice (GMP) grade production, essential for the manufacture of clinical and commercial batches.

This project contributes to strengthening French excellence in research and innovation in the field of advanced therapies, aligned with the France 2030 objectives to promote technological innovation and competitiveness in health.